<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id>
<journal-title>Frontiers in Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmicb.2021.729472</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Microbiology</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Technological Advances Improving Recombinant Protein Production in Bacteria</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Ow</surname> <given-names>Dave Siak-Wei</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/281332/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Oh</surname> <given-names>Min-Kyu</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1052290/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Chiang</surname> <given-names>Chung-Jen</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chao</surname> <given-names>Yun-Peng</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1047529/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Microbial Cell Bioprocessing Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research (A&#x0002A;STAR)</institution>, <addr-line>Singapore</addr-line>, <country>Singapore</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Chemical and Biological Engineering, Korea University</institution>, <addr-line>Seoul</addr-line>, <country>South Korea</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Medical Laboratory Science and Biotechnology, China Medical University</institution>, <addr-line>Taichung</addr-line>, <country>Taiwan</country></aff>
<aff id="aff4"><sup>4</sup><institution>Department of Chemical Engineering, Feng Chia University</institution>, <addr-line>Taichung</addr-line>, <country>Taiwan</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited and reviewed by: C. Perry Chou, University of Waterloo, Canada</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Dave Siak-Wei Ow <email>dave_ow&#x00040;bti.a-star.edu.sg</email></corresp>
<fn fn-type="other" id="fn001"><p>This article was submitted to Microbiotechnology, a section of the journal Frontiers in Microbiology</p></fn></author-notes>
<pub-date pub-type="epub">
<day>26</day>
<month>07</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>12</volume>
<elocation-id>729472</elocation-id>
<history>
<date date-type="received">
<day>23</day>
<month>06</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>06</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2021 Ow, Oh, Chiang and Chao.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Ow, Oh, Chiang and Chao</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<related-article id="RA1" related-article-type="commentary-article" xlink:href="https://www.frontiersin.org/research-topics/15736/technological-advances-improving-recombinant-protein-production-in-bacteria" ext-link-type="uri">Editorial on the Research Topic <article-title>Technological Advances Improving Recombinant Protein Production in Bacteria</article-title></related-article>
<kwd-group>
<kwd>recombinant protein production</kwd>
<kwd><italic>Escherichia coli</italic></kwd>
<kwd><italic>Vibrio natriegens</italic></kwd>
<kwd><italic>Lactiplantibacillus plantarum</italic></kwd>
<kwd>central metabolism</kwd>
<kwd>metabolic burden</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="10"/>
<page-count count="3"/>
<word-count count="1692"/>
</counts>
</article-meta>
</front>
<body>
<p>The advancement in synthetic biology enables reprogramming of microbial cell factories to overproduce recombinant proteins for an array of useful applications. Recombinant protein products of importance generally include growth factors and hormones, antibodies, enzymes and vaccines (Rosano and Ceccarelli, <xref ref-type="bibr" rid="B9">2014</xref>). The market of recombinant proteins is forecasted to grow at an estimated compound annual growth rate (CAGR) of between 9.8 and 12.2% (VynZ Research, <xref ref-type="bibr" rid="B10">2019</xref>; MarketsandMarket Inc., <xref ref-type="bibr" rid="B5">2021</xref>). Among those products, growth factors and hormones have the largest market share; growth factors are signaling proteins that regulate cellular processes involving proliferation, differentiation, inflammation and angiogenesis. Recombinant growth factors have been conventionally used as therapeutics for wound healing and diseases, and they increasingly serve as cosmetic additives and as a supplement in serum-free media for cultivated meats (Kim et al., <xref ref-type="bibr" rid="B3">2021</xref>; O&#x00027;Neill et al., <xref ref-type="bibr" rid="B6">2021</xref>). In particular, the current COVID-19 pandemic has called on efforts on the development of recombinant protein-based vaccines and therapies. Emerging data suggest that recombinant protein vaccines potentially complement the mRNA and viral vector vaccines (Pollet et al., <xref ref-type="bibr" rid="B8">2021</xref>).</p>
<p>There is a pressing need to design economically sustainable processes to achieve efficient recombinant protein production (RPP). Bacterial expression systems are commonly employed to address this issue because their genomes are relatively simple to manipulate, they can be cultured in cost-effective media, and the production scheme is easily scalable (Rosano and Ceccarelli, <xref ref-type="bibr" rid="B9">2014</xref>; MarketsandMarket Inc., <xref ref-type="bibr" rid="B5">2021</xref>). Large-scale production of many recombinant proteins remains challenging, especially for those with multiple disulfide bonds or from mammalian origins. The precursor metabolites and energy required to fuel cellular activity and protein biosynthesis come from central metabolic pathways (Papagianni, <xref ref-type="bibr" rid="B7">2012</xref>). However, RPP often perturbs cell physiology as a result of imbalanced carbon flux, energy drain, and impaired global regulation in central and cellular metabolism. This in turn results in a metabolic burden leading to a bacterial stress response, which further hampers cell growth and protein synthesis (Glick, <xref ref-type="bibr" rid="B2">1995</xref>; Li and Rinas, <xref ref-type="bibr" rid="B4">2020</xref>). Further genetic strategies are needed to overcome this bottleneck in RPP.</p>
<p>The current Research Topic consists of six original research articles that propose various molecular and downstream strategies for enhancing RPP in bacteria. In prokaryotes, central metabolism and host physiology are coordinated by a complex network of global and specific local transcriptional regulators (Chubukov et al., <xref ref-type="bibr" rid="B1">2014</xref>). FlhC is the master regulator for flagellar assembly in <italic>E. coli</italic>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmicb.2021.655072">Han et al.</ext-link> reported the construction of a <italic>flhC</italic> knockout <italic>E. coli</italic> strain deficient in <italic>ptsG</italic> (which encodes the glucose transporter). The FlhC/PtsG mutant displayed higher ATP and NADPH accumulation, and the <sup>13</sup>C-labeling metabolic flux analysis showed a carbon flux increase in both the pentose phosphate pathway and the tricarboxylic acid cycle. Interestingly, the expression of the enhanced green fluorescent protein (EGFP) was increased in the FlhC/PtsG mutant which restored the growth rate. In another study, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmicb.2021.675729">Wang et al.</ext-link> illustrated that the addition of a C-terminal 5xCys polycysteine tag to a Streptococcal protein G led to the sequestration of the tagged recombinant protein in inclusion bodies (IBs). This in turn caused the metabolic perturbation in <italic>E. coli</italic>. Two methods were proposed to improve RPP including (1) deletion of <italic>oxyRS</italic>, a global regulator of the oxidative stress response and (2) implementation of a redox-based autoinduction strategy by integrating a quorum sensing (QS) switch. As a result, the highest yield of the soluble 5xCys-tagged Streptococcal protein G was obtained in the OxyRS mutant equipped with the autoinduction system.</p>
<p>Synthetic biology approaches were applied for the smart design of a genetic switch in <italic>E. coli</italic>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmicb.2021.663642">Lo et al.</ext-link> employed a two-layer genetic controller to regulate bioconversion enzyme expression based on the availability of raw materials and other nutrients. This allowed <italic>E. coli</italic> to activate the bioconversion process to produce a precursor intermediate, &#x003B2;-ketoadipic acid, without the need for chemical inducers. As a result, two commodity chemicals, adipic acid and levulinic acid, were synthesized from &#x003B2;-ketoadipic acid. This approach may see interesting and potential applications in RPP. As well-recognized, the overexpression of recombinant proteins in <italic>E. coli</italic> commonly leads to the formation of protein aggregates or inclusion bodies (IBs). <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmicb.2021.618559">Singhvi et al.</ext-link> investigated the use of a contemporary freeze&#x02013;thaw-based solubilization method. This allowed for the recovery of functionally active human growth hormone (hGH) and L-asparaginase from IBs. In general, the freeze&#x02013;thaw method enabled the solubilisation of hGH aggregates and destabilization of the tetrameric L-asparaginase protein. The purified hGH displayed bioactivity in the improved proliferation of rat lymphoma cells.</p>
<p>The work by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmicb.2021.627181">Xu et al.</ext-link> explored Gram-negative bacterium, <italic>Vibrio natriegens</italic>, as a production host based on the pET expression system. A total of 196 pET plasmids encoding different proteins were transformed into a <italic>V. natriegens</italic> strain with an integrated T7 RNA polymerase. Twenty constructs showed better soluble expression in <italic>V. natriegens</italic> than in <italic>E. coli</italic>. The result indicates that the spectrum of well-expressed proteins in <italic>V. natriegens</italic> is comparable to that of <italic>E. coli</italic>. This study suggests that <italic>V. natriegens</italic> could be a valuable alternative host to <italic>E. coli</italic>. Finally, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmicb.2021.689413">Tran et al.</ext-link> investigated the application of the Gram-positive <italic>Lactiplantibacillus plantarum</italic> WCFS1 system for the secretion and production of the &#x003B1;-amylase AmyL from <italic>L. plantarum</italic> S21. They compared 5 secretion signal peptides and found that the highest secreted yield of the enzyme was obtained by a Sec-type signal peptide from <italic>L. plantarum</italic> WCFS1 (Lp_2145). The activity and mRNA level of &#x003B1;-amylase in recombinant <italic>L. plantarum</italic> WCFS1 were analyzed along the time course. This information provided the basis to correlate the secretion yield with the transcription level, which led to the best strategy for the efficient production of the protein.</p>
<p>As grasped from the reports, the naturally balanced and interwoven network of cellular metabolism is commonly perturbed by the overproduction of foreign proteins in bacteria host. Effective implementation of synthetic biology concepts&#x02014;design, build, test and learn&#x02014;as underscored in the present topic can open up new perspectives in biotechnology. This will lead us toward a more sustainable bio-economy with wider applications of recombinant proteins in daily life.</p>
<sec id="s1">
<title>Author Contributions</title>
<p>DO drafted the manuscript. M-KO, C-JC, and Y-PC edited and proof-read the manuscript. All authors made a substantial contribution to the work and approved it for publication.</p>
</sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s2">
<title>Publisher&#x00027;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<ack><p>DO would like to thank Richie Tay and Tan Ding Jie for proof-reading the article and the Agency for Science, Technology and Research (A&#x0002A;STAR) for supporting this work. This project was supported by the Singapore Food Agency (SFA) and A&#x0002A;STAR, under its 1st Alternative proteins seed challenge (Singapore Food Story R&#x00026;D Programme theme 2: Future Foods-Alternative proteins, Ref: W20W2D0005).</p></ack>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chubukov</surname> <given-names>V.</given-names></name> <name><surname>Gerosa</surname> <given-names>L.</given-names></name> <name><surname>Kochanowski</surname> <given-names>K.</given-names></name> <name><surname>Sauer</surname> <given-names>U.</given-names></name></person-group> (<year>2014</year>). <article-title>Coordination of microbial metabolism</article-title>. <source>Nat. Rev. Microbiol.</source> <volume>12</volume>, <fpage>327</fpage>&#x02013;<lpage>340</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro3238</pub-id><pub-id pub-id-type="pmid">24658329</pub-id></citation></ref>
<ref id="B2">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glick</surname> <given-names>B. R.</given-names></name></person-group> (<year>1995</year>). <article-title>Metabolic load and heterologous gene expression</article-title>. <source>Biotechnol. Adv.</source> <volume>13</volume>, <fpage>247</fpage>&#x02013;<lpage>261</lpage>. <pub-id pub-id-type="doi">10.1016/0734-9750(95)00004-A</pub-id><pub-id pub-id-type="pmid">14537822</pub-id></citation></ref>
<ref id="B3">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>Y. S.</given-names></name> <name><surname>Lee</surname> <given-names>H. J.</given-names></name> <name><surname>Han</surname> <given-names>M. H.</given-names></name> <name><surname>Yoon</surname> <given-names>N. K.</given-names></name> <name><surname>Kim</surname> <given-names>Y. C.</given-names></name> <name><surname>Ahn</surname> <given-names>J.</given-names></name></person-group> (<year>2021</year>). <article-title>Effective production of human growth factors in <italic>Escherichia coli</italic> by fusing with small protein 6HFh8</article-title>. <source>Microb. Cell Fact</source> <volume>20</volume>:<fpage>9</fpage>. <pub-id pub-id-type="doi">10.1186/s12934-020-01502-1</pub-id><pub-id pub-id-type="pmid">33413407</pub-id></citation></ref>
<ref id="B4">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Z.</given-names></name> <name><surname>Rinas</surname> <given-names>U.</given-names></name></person-group> (<year>2020</year>). <article-title>Recombinant protein production associated growth inhibition results mainly from transcription and not from translation</article-title>. <source>Microb. Cell Fact</source>. <volume>19</volume>:<fpage>83</fpage>. <pub-id pub-id-type="doi">10.1186/s12934-020-01343-y</pub-id><pub-id pub-id-type="pmid">30720114</pub-id></citation></ref>
<ref id="B5">
<citation citation-type="web"><person-group person-group-type="author"><collab>MarketsandMarket Inc.</collab></person-group> (<year>2021</year>). <source>Recombinant Proteins Market. Report Code: BT 7839</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.marketsandmarkets.com/PressReleases/recombinant-proteins.asp">https://www.marketsandmarkets.com/PressReleases/recombinant-proteins.asp</ext-link> (accessed June 14, 2021).</citation></ref>
<ref id="B6">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>O&#x00027;Neill</surname> <given-names>E. N.</given-names></name> <name><surname>Cosenza</surname> <given-names>Z. A.</given-names></name> <name><surname>Baar</surname> <given-names>K.</given-names></name> <name><surname>Block</surname> <given-names>D. E.</given-names></name></person-group> (<year>2021</year>). <article-title>Considerations for the development of cost-effective cell culture media for cultivated meat production</article-title>. <source>Compr. Rev. Food Sci. Food Saf</source>. <volume>20</volume>, <fpage>686</fpage>&#x02013;<lpage>709</lpage>. <pub-id pub-id-type="doi">10.1111/1541-4337.12678</pub-id><pub-id pub-id-type="pmid">33325139</pub-id></citation></ref>
<ref id="B7">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Papagianni</surname> <given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>Recent advances in engineering the central carbon metabolism of industrially important bacteria</article-title>. <source>Microb. Cell Fact.</source> <volume>11</volume>:<fpage>50</fpage>. <pub-id pub-id-type="doi">10.1186/1475-2859-11-50</pub-id><pub-id pub-id-type="pmid">22545791</pub-id></citation></ref>
<ref id="B8">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pollet</surname> <given-names>J.</given-names></name> <name><surname>Chen</surname> <given-names>W. H.</given-names></name> <name><surname>Strycha</surname> <given-names>U.</given-names></name></person-group> (<year>2021</year>). <article-title>Recombinant protein vaccines, a proven approach against coronavirus pandemics</article-title>. <source>Adv. Drug Deliv. Rev</source>. <volume>170</volume>, <fpage>71</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2021.01.001</pub-id><pub-id pub-id-type="pmid">33421475</pub-id></citation></ref>
<ref id="B9">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosano</surname> <given-names>G. L.</given-names></name> <name><surname>Ceccarelli</surname> <given-names>E. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Recombinant protein expression in <italic>Escherichia coli</italic>: advances and challenges</article-title>. <source>Front. Microbiol</source>. <volume>5</volume>:<fpage>172</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2014.00172</pub-id><pub-id pub-id-type="pmid">24860555</pub-id></citation></ref>
<ref id="B10">
<citation citation-type="web"><person-group person-group-type="author"><collab>VynZ Research</collab></person-group> (<year>2019</year>). <source>Global Protein Expression Market Estimate and Forecast to 2024. Report Code: VRHC1025</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.vynzresearch.com/healthcare/protein-expression-market">https://www.vynzresearch.com/healthcare/protein-expression-market</ext-link> (accessed June 14, 2021).</citation></ref>
</ref-list> 
</back>
</article>
